KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables - Net: 2017-2025

Historic Receivables - Net for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $2.0 billion.

  • Moderna's Receivables - Net fell 25.92% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 25.92%. This contributed to the annual value of $698.0 million for FY2024, which is 55.93% down from last year.
  • As of Q3 2025, Moderna's Receivables - Net stood at $2.0 billion, which was up 678.46% from $260.0 million recorded in Q2 2025.
  • Moderna's 5-year Receivables - Net high stood at $3.2 billion for Q1 2021, and its period low was $232.0 million during Q2 2023.
  • For the 3-year period, Moderna's Receivables - Net averaged around $1.1 billion, with its median value being $698.0 million (2024).
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 57,047.94% in 2021, then tumbled by 91.38% in 2023.
  • Quarterly analysis of 5 years shows Moderna's Receivables - Net stood at $3.2 billion in 2021, then plummeted by 56.38% to $1.4 billion in 2022, then rose by 14.37% to $1.6 billion in 2023, then crashed by 55.93% to $698.0 million in 2024, then decreased by 25.92% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q3 2025, $260.0 million for Q2 2025, and $249.0 million during Q1 2025.